key: cord-0887069-5f4u5mif
authors: De Vriese, An S; Van Praet, Jens; Reynders, Marijke; Heylen, Line; Viaene, Liesbeth; Caluwé, Rogier; Schoutteten, Melanie; De Bacquer, Dirk
title: Longevity and correlation with disease severity of the humoral and cellular response to SARS-CoV-2 infection in haemodialysis patients
date: 2021-08-13
journal: Clin Kidney J
DOI: 10.1093/ckj/sfab147
sha: 0e7b6f9d905afba19bfda19cd0f0fa7158db2942
doc_id: 887069
cord_uid: 5f4u5mif

nan

Following severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, the large majority of haemodialysis (HD) patients rapidly seroconvert [1] [2] [3] , with robust and durable serological responses up to 10 months [4] . These observations appear non-sequitur in view of the well-known immune dysfunction of HD patients, resulting in slower viral clearance and higher case fatality rates of SARS-CoV-2 infection, as well as impaired responses to SARS-CoV-2 vaccination [5] . A potential explanation may be that dialysis patients develop more severe disease with prolonged viral shedding and higher levels of pro-inflammatory cytokines, resulting in more intense immune stimulation. In a study of 2215 HD patients, older and diabetic patients had slightly higher antibody levels, but data on disease severity were not available [6] .

In the general population, robust T-cell responses have been observed in asymptomatic patients even in the absence of detectable antibodies, suggesting that T-cell immunity develops independently of disease severity [7] . A cohort of 14 HD patients, sampled a mean of 40 days after coronavirus disease 2019 diagnosis, displayed T-cell responses of similar intensity to those of patients with normal renal function [8] . Currently there are no data on the durability and correlation with disease severity of T-cell immunity in HD patients.

Of the 569 patients on HD in March 2021, 41 had a history of polymerase chain reaction (PCR)-confirmed SARS-CoV-2 infection, of which 24 had asymptomatic or mild disease and 17 had severe disease requiring hospitalization (Supplementary data, Serological responses persisted up to >1 year, with a faster decay of anti-nucleocapsid protein (anti-N) immunoglobulin G (IgG) than anti-spike protein (anti-S) IgG ( Figure 1A and B) . Patients with severe disease had higher antibody levels ( Table 1 ), but the decay trajectory was similar. Interferon-c production by peripheral blood CD4 þ and CD8 þ lymphocytes was unaffected by disease severity (Table 1 ) and could be detected up to >1 year after infection but did not display a clear pattern of evolution over time ( Figure 1C ).

In conclusion, the humoral response to SARS-CoV-2 infection in HD patients is a marker of disease severity. Prolonged viral antigen exposure and production of inflammatory cytokines Letter to the Editor Clinical Kidney Journal due to a more severe disease course may explain the intense and long-lasting antibody production in HD patients. Conversely, the cellular immune response is unaffected by disease severity and appears to be governed by as yet undetermined factors.

This research was supported by a grant of Amgen (DONAT ION-331036). The funding source had no role in the design, conduct, or analysis of the study or the decision to submit the manuscript for publication. According to linear models for log10-transformed outcomes. GMT, geometric mean titre; GMC, geometric mean concentration.

IgG antibodyresponse to SARS-CoV-2 infection and viral RNA persistence in patients on maintenance hemodialysis

Kinetics of anti-SARS-CoV-2 IgG antibodies in hemodialysis patients six months after infection

The cut-off for positivity (dashed line) was 50 AU/mL and the conversion factor to the World Health Organization binding antibody units (BAU/mL) is BAU/mL ¼ 0.142 Â AU/mL. Anti-N IgG was measured by a CMIA on the same ARCHITECT i analyser (SARS-CoV-2 IgG assay, Abbott). A signal:cut-off ratio !1.4 (dashed line) was interpreted as reactive

Longevity of SARS-CoV-2 immune responses in hemodialysis patients and protection against reinfection

IgG SARS-CoV-2 antibodies persist at least for 10 months in patients on hemodialysis

Immune response to SARS-CoV-2 infection and vaccination in patients receiving kidney replacement therapy

Serial SARS-CoV-2 receptor-binding domain antibody responses in patients receiving dialysis

Robust T cell immunity in convalescent individuals with asymptomatic or mild COVID-19

SARS-CoV-2-reactive cellular and humoral immunity in hemodialysis population

None declared.